- Achillion (ACHN) is up 8.7% before the bell after a poster presentation at AASLD outlines the "preclinical profile" of ACH-3422.
- The presentation "details the potent and specific inhibition of HCV NS5B polymerase, demonstrates [the] low risk for mitochondrial toxicity [and shows] high efficiency in the conversion of ACH-3422 into the triphosphate within human hepatocyte cell lines."
- In sum, the company says it expects to initiate first-in-human and proof-of-concept trials in H1 2014. (PR)
Achillion rallies on ACH-3422 poster presentation
Nov 4 2013, 08:29 ET